Evidence map›Paper›PMID 40660980›Full record

ReviewZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2025

[Sounding the call for functional cure of hepatitis B and opening a new era of combination therapy].

C Cheng, X E Liang, Z H Liu, J L Hou

Abstract readReviewEnglish Abstract
In one paragraph

Review in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

C ChengGuangdong Institute of Hepatology, Guangzhou 510515, China.
X E LiangGuangdong Institute of Hepatology, Guangzhou 510515, China Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Z H LiuGuangdong Institute of Hepatology, Guangzhou 510515, China Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
J L HouGuangdong Institute of Hepatology, Guangzhou 510515, China Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.

Funding

National Key Research and Development Program of China 2022YFC2303600
6 · The paper itself

Abstract

Functional cure (i.e., clinical cure) of chronic hepatitis B (CHB) is a core research objective in the field of hepatology. With the revision of the Expert opinions on the technical guiding Principles for clinical trials of drugs in the treatment of chronic hepatitis B virus infection, this article concisely reviews the evolving concept of functional cure for hepatitis B, research progress on the dynamic trajectories and threshold of key serological markers (such as HBsAg/anti-HBs), strategies for safety evaluation of treatment discontinuation, and the importance of building a collaborative innovation ecosystem involving scientific research, industry, healthcare, policy, and societal forces. Through multidimensional technological breakthroughs and interdisciplinary collaboration, the functional cure rate of chronic hepatitis B infection is expected to improve significantly over the next 5-10 years, laying the foundation for achieving the World Health Organization (WHO)'s goal of eliminating viral hepatitis as a public health threat by 2030.

Indexed as

Antiviral AgentsHepatitis B, ChronicDrug Therapy, CombinationHepatitis B Surface AntigensHepatitis B virusHumansAntiviral AgentsHepatitis B Surface Antigens

Identifiers

PMID40660980
PMCPMC12861758

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.